Athena Countouriotis
CIK 1571469 · President & CEO · last filed 2026-06-04
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.29M
Companies
8
Total Filings
44
Lifetime Open-Market Net
-$7.13M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BMRN | Director | 21,040 | $55.95 | $1.18M | $0 | 4 | 2026-06-04 |
| PASG | Director | 18,900 | $5.81 | $109.8K | $309.9K | 9 | 2026-05-21 |
| IOVA | Director | — | $4.08 | — | $0 | 8 | 2025-06-17 |
| Turning Point Therapeutics, Inc. (TPTX) Delisted | President & CEO | 0 | $76.01 | $0 | -$7.44M | 8 | 2022-08-17 |
| Cardiff Oncology, Inc. (TROV) Delisted | Director | — | — | — | $0 | 2 | 2019-06-24 |
| Adverum Biotechnologies, Inc. (ADVM) Delisted | SVP, Chief Medical Officer | 150,000 | $4.36 | $654.0K | $0 | 2 | 2018-02-20 |
| HALOZYME THERAPEUTICS, INC. (HTI) Delisted | SVP and Chief Medical Officer | 45,977 | — | — | $0 | 8 | 2017-02-24 |
| AMBIT BIOSCIENCES CORP (AMBI) Delisted | Chief Medical Officer | — | $0.54 | — | $0 | 3 | 2014-11-12 |
Recent Filings · Page 4 of 5
44 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-02-20 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-01-25 | Cardiff Oncology, Inc. (TROV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-06-21 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Grant (A) | +150,000 | $0 | EDGAR |
| 2017-02-24 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-02-06 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Mixed | +11,596 | -$84.6K | EDGAR |
| 2017-01-09 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Exer (M) | +7,500 | $0 | EDGAR |
| 2016-07-05 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Mixed | +6,343 | -$923 | EDGAR |
| 2016-02-04 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-01-07 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Mixed | +4,243 | -$53.4K | EDGAR |
| 2016-01-04 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Mixed | +9,395 | -$98.0K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.